Drugs /

glycosylated recombinant human interleukin-7

Back to Drugs List

Overview

NCI Definition [1]:
A glycosylated recombinant protein which is chemically identical to or similar to endogenous human interleukin-7 (IL-7) with hematopoietic and immunopotentiating activities. Naturally produced by bone marrow, thymic stromal, and spleen cells, the cytokine interleukin-7 is a hematopoietic growth factor for progenitor B cells and T cells, stimulating proliferation and differentiation of mature T-cells and natural killer (NK) cells. As with glycosylated endogenous proteins, glycosylation of recombinant proteins may fundamentally affect their biological activity, function, clearance from circulation, and antigenicity; glycosylation of recombinant proteins that are chemically idenitical to or similar to endogenous proteins may render protein structures and biological activities that are more similar to those of glycosylated endogenous proteins.

Clinical Trials

View Clinical Trials for glycosylated recombinant human interleukin-7

Glycosylated recombinant human interleukin-7 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating glycosylated recombinant human interleukin-7, 1 is phase 2 (1 open).

Bladder urothelial carcinoma, renal pelvis urothelial carcinoma, and ureter urothelial carcinoma are the most common diseases being investigated in glycosylated recombinant human interleukin-7 clinical trials [2].

Drug Details

Synonyms [2]:
glycosylated rhil-7, cyt107, glycosylated rhil-7
NCIT ID [1]:
C77879

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.